205 related articles for article (PubMed ID: 31704853)
1. The mTOR Signaling Pathway Is Associated With the Prognosis of Malignant Pleural Mesothelioma After Multimodality Therapy.
Kuroda A; Matsumoto S; Fukuda A; Nakamichi T; Nakamura A; Hashimoto M; Takuwa T; Kondo N; Tsujimura T; Nakano T; Hasegawa S
Anticancer Res; 2019 Nov; 39(11):6241-6247. PubMed ID: 31704853
[TBL] [Abstract][Full Text] [Related]
2. Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery.
Frischknecht L; Meerang M; Soltermann A; Stahel R; Moch H; Seifert B; Weder W; Opitz I
J Thorac Cardiovasc Surg; 2015 Jun; 149(6):1539-46.e1. PubMed ID: 25840756
[TBL] [Abstract][Full Text] [Related]
3. PI3K/mTOR signaling in mesothelioma patients treated with induction chemotherapy followed by extrapleural pneumonectomy.
Bitanihirwe BK; Meerang M; Friess M; Soltermann A; Frischknecht L; Thies S; Felley-Bosco E; Tsao MS; Allo G; de Perrot M; Seifert B; Moch H; Stahel R; Weder W; Opitz I
J Thorac Oncol; 2014 Feb; 9(2):239-47. PubMed ID: 24419422
[TBL] [Abstract][Full Text] [Related]
4. Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy.
Thieke C; Nicolay NH; Sterzing F; Hoffmann H; Roeder F; Safi S; Debus J; Huber PE
Radiat Oncol; 2015 Dec; 10():267. PubMed ID: 26715491
[TBL] [Abstract][Full Text] [Related]
5. Combined modality treatment for malignant pleural mesothelioma: a single-centre long-term survival analysis using extrapleural pneumonectomy.
Frick AE; Nackaerts K; Moons J; Lievens Y; Verbeken E; Lambrecht M; Coolen J; Dooms C; Vansteenkiste J; De Leyn P; Nafteux P
Eur J Cardiothorac Surg; 2019 May; 55(5):934-941. PubMed ID: 30535191
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.
Stahel RA; Riesterer O; Xyrafas A; Opitz I; Beyeler M; Ochsenbein A; Früh M; Cathomas R; Nackaerts K; Peters S; Mamot C; Zippelius A; Mordasini C; Caspar CB; Eckhardt K; Schmid RA; Aebersold DM; Gautschi O; Nagel W; Töpfer M; Krayenbuehl J; Ribi K; Ciernik IF; Weder W
Lancet Oncol; 2015 Dec; 16(16):1651-8. PubMed ID: 26538423
[TBL] [Abstract][Full Text] [Related]
7. Trimodality strategy for treating malignant pleural mesothelioma: results of a feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation (Japan Mesothelioma Interest Group 0601 Trial).
Hasegawa S; Okada M; Tanaka F; Yamanaka T; Soejima T; Kamikonya N; Tsujimura T; Fukuoka K; Yokoi K; Nakano T
Int J Clin Oncol; 2016 Jun; 21(3):523-30. PubMed ID: 26577445
[TBL] [Abstract][Full Text] [Related]
8. Systemic Therapy Use and Outcomes After Relapse from Preoperative Radiation and Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma.
Soldera SV; Kavanagh J; Pintilie M; Leighl NB; de Perrot M; Cho J; Hope A; Feld R; Bradbury PA
Oncologist; 2019 Jul; 24(7):e510-e517. PubMed ID: 30478189
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales.
Linton A; Pavlakis N; O'Connell R; Soeberg M; Kao S; Clarke S; Vardy J; van Zandwijk N
Br J Cancer; 2014 Oct; 111(9):1860-9. PubMed ID: 25188323
[TBL] [Abstract][Full Text] [Related]
10. Interim results of pleurectomy/decortication and intraoperative intrapleural hyperthermic cisplatin perfusion for patients with malignant pleural mesothelioma intolerable to extrapleural pneumonectomy.
Ishibashi H; Kobayashi M; Takasaki C; Okubo K
Gen Thorac Cardiovasc Surg; 2015 Jul; 63(7):395-400. PubMed ID: 25750109
[TBL] [Abstract][Full Text] [Related]
11. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
Krug LM; Pass HI; Rusch VW; Kindler HL; Sugarbaker DJ; Rosenzweig KE; Flores R; Friedberg JS; Pisters K; Monberg M; Obasaju CK; Vogelzang NJ
J Clin Oncol; 2009 Jun; 27(18):3007-13. PubMed ID: 19364962
[TBL] [Abstract][Full Text] [Related]
12. Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma.
Shaikh F; Zauderer MG; von Reibnitz D; Wu AJ; Yorke ED; Foster A; Shi W; Zhang Z; Adusumilli PS; Rosenzweig KE; Krug LM; Rusch VW; Rimner A
J Thorac Oncol; 2017 Jun; 12(6):993-1000. PubMed ID: 28341225
[TBL] [Abstract][Full Text] [Related]
13. Updated patterns of failure after multimodality therapy for malignant pleural mesothelioma.
Baldini EH; Richards WG; Gill RR; Goodman BM; Winfrey OK; Eisen HM; Mak RH; Chen AB; Kozono DE; Bueno R; Sugarbaker DJ
J Thorac Cardiovasc Surg; 2015 May; 149(5):1374-81. PubMed ID: 25772281
[TBL] [Abstract][Full Text] [Related]
14. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial.
Flores RM; Krug LM; Rosenzweig KE; Venkatraman E; Vincent A; Heelan R; Akhurst T; Rusch VW
J Thorac Oncol; 2006 May; 1(4):289-95. PubMed ID: 17409872
[TBL] [Abstract][Full Text] [Related]
15. A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma.
Cao C; Tian D; Park J; Allan J; Pataky KA; Yan TD
Lung Cancer; 2014 Feb; 83(2):240-5. PubMed ID: 24360321
[TBL] [Abstract][Full Text] [Related]
16. Outcome for patients with malignant pleural mesothelioma referred for Trimodality therapy in Western Australia.
Hasani A; Alvarez JM; Wyatt JM; Bydder S; Millward M; Byrne M; Musk AW; Nowak AK
J Thorac Oncol; 2009 Aug; 4(8):1010-6. PubMed ID: 19546819
[TBL] [Abstract][Full Text] [Related]
17. Induction chemotherapy, extrapleural pneumonectomy, and radiotherapy in the treatment of malignant pleural mesothelioma: the Memorial Sloan-Kettering experience.
Flores RM
Lung Cancer; 2005 Jul; 49 Suppl 1():S71-4. PubMed ID: 15950805
[TBL] [Abstract][Full Text] [Related]
18. Early-stage Clinical Characterization of Malignant Pleural Mesothelioma.
Negi Y; Kuribayashi K; Funaguchi N; Doi H; Mikami K; Minami T; Takuwa T; Yokoi T; Hasegawa S; Kijima T
In Vivo; 2018; 32(5):1169-1174. PubMed ID: 30150440
[TBL] [Abstract][Full Text] [Related]
19. A feasibility study evaluating Surgery for Mesothelioma After Radiation Therapy: the "SMART" approach for resectable malignant pleural mesothelioma.
Cho BC; Feld R; Leighl N; Opitz I; Anraku M; Tsao MS; Hwang DM; Hope A; de Perrot M
J Thorac Oncol; 2014 Mar; 9(3):397-402. PubMed ID: 24445595
[TBL] [Abstract][Full Text] [Related]
20. Multimodality treatment of malignant pleural mesothelioma.
Berzenji L; Van Schil P
F1000Res; 2018; 7():. PubMed ID: 30410726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
